Evidence map›Paper›PMID 28703015›Full record

SynthesisCanadian journal of psychiatry. Revue canadienne de psychiatrie2017

Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Gary Remington, Donald Addington, William Honer, Zahinoor Ismail, Thomas Raedler, Michael Teehan

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. The Australian and New Zealand journal of psychiatry · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Efficacy and Safety of Olanzapine Long-acting Injection in Schizophrenia and Schizoaffective Disorder: A Systematic Review and Meta-analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gary Remington1 Departments of Psychiatry and Psychological Clinical Science, University of Toronto, Toronto, Canada.
Donald Addington3 Department of Psychiatry, University of Calgary, Calgary, Canada.
William Honer5 Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Zahinoor Ismail4 Hotchkiss Brain Institute and Matheson Centre for Mental Health Research and Education, Calgary, Canada.
Thomas Raedler7 Psychopharmacology Research Unit, Department of Psychiatry, University of Calgary, Calgary, Canada.
Michael Teehan8 Department of Psychiatry, Dalhousie University, Halifax, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.

methodGuidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline.

resultsRecommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.

conclusionsIn most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

Indexed as

AdultAntipsychotic AgentsCanadaEvidence-Based MedicineHumansPractice Guidelines as TopicSchizophreniaAntipsychotic Agentsadult psychiatryantipsychoticsclinical practice guidelinepharmacotherapyschizophreniasystematic review

Identifiers

PMID28703015
PMCPMC5593252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.